Arena Capital Advisors LLC CA lowered its holdings in shares of European Biotech Acquisition Corp. (NASDAQ:EBAC – Get Rating) by 94.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 5,717 shares of the company's stock after selling 98,025 shares during the quarter. Arena Capital Advisors LLC CA's holdings in European Biotech Acquisition were worth $56,000 as of its most recent filing with the Securities & Exchange Commission.
European Biotech Acquisition Price Performance
European Biotech Acquisition stock remained flat at $9.99 during mid-day trading on Friday. 52,698 shares of the company traded hands, compared to its average volume of 30,297. European Biotech Acquisition Corp. has a one year low of $9.66 and a one year high of $10.50. The stock's 50 day moving average is $9.94.
Get European Biotech Acquisition alerts:European Biotech Acquisition Company Profile
(Get Rating)
European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. European Biotech Acquisition Corp. was incorporated in 2021 and is based in Amsterdam, the Netherlands.Read More
- Get a free copy of the StockNews.com research report on European Biotech Acquisition (EBAC)
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Want to see what other hedge funds are holding EBAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for European Biotech Acquisition Corp. (NASDAQ:EBAC – Get Rating).
Receive News & Ratings for European Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for European Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.